Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRALNASDAQ:PODDNASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRALGrail$40.03+4.4%$33.24$12.33▼$63.99$1.44BN/A1.27 million shs2.59 million shsPODDInsulet$305.66-2.0%$282.34$173.00▼$329.33$21.51B1.37709,297 shs906,431 shsTMDXTransMedics Group$139.40+0.3%$101.54$55.00▼$177.37$4.72B2.11.36 million shs636,108 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRALGrail0.00%+1.75%+8.98%+19.54%+3,835,999,900.00%PODDInsulet0.00%-3.92%+0.43%+31.52%+62.87%TMDXTransMedics Group0.00%+8.68%+24.71%+110.59%+1.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRALGrail0.3745 of 5 stars1.11.00.00.02.10.80.6PODDInsulet4.1563 of 5 stars2.43.00.04.93.30.81.9TMDXTransMedics Group1.4791 of 5 stars1.43.00.00.01.42.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRALGrail 2.25Hold$31.50-21.08% DownsidePODDInsulet 2.82Moderate Buy$318.414.02% UpsideTMDXTransMedics Group 2.80Moderate Buy$125.11-10.60% DownsideCurrent Analyst Ratings BreakdownLatest GRAL, TMDX, and PODD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.006/3/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/30/2025PODDInsuletThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$380.005/27/2025PODDInsuletRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$328.00 ➝ $360.005/22/2025PODDInsuletCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$320.00 ➝ $380.005/16/2025PODDInsuletSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/14/2025GRALGrailCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $43.005/13/2025PODDInsuletWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradePeer Perform ➝ Outperform$350.005/9/2025PODDInsuletOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$312.00 ➝ $324.005/9/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.005/9/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.00(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRALGrail$130.71M10.99N/AN/AN/A∞PODDInsulet$2.20B9.80$4.03 per share75.96$10.49 per share29.18TMDXTransMedics Group$488.23M9.70$0.26 per share530.08$4.20 per share33.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRALGrailN/A-$60.99N/AN/AN/AN/AN/AN/A8/12/2025 (Estimated)PODDInsulet$206.30M$5.5652.8761.593.6220.19%24.46%8.33%8/6/2025 (Estimated)TMDXTransMedics Group-$25.03M$1.36148.7497.86N/A8.14%18.74%4.39%7/30/2025 (Estimated)Latest GRAL, TMDX, and PODD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025GRALGrail-$4.03-$3.10+$0.93-$3.10$35.80 million$31.84 million5/8/2025Q1 2025PODDInsulet$0.81$1.02+$0.21$0.50$543.20 million$569.00 million5/8/2025Q1 2025TMDXTransMedics Group$0.29$0.70+$0.41$0.70$123.39 million$143.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRALGrailN/AN/AN/AN/AN/APODDInsuletN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRALGrailN/A9.659.65PODDInsulet1.213.682.80TMDXTransMedics Group2.428.207.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRALGrailN/APODDInsuletN/ATMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipGRALGrail1.85%PODDInsulet0.39%TMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRALGrail1,36035.97 millionN/AOptionablePODDInsulet2,60070.38 million69.82 millionOptionableTMDXTransMedics Group21033.82 million31.21 millionOptionableGRAL, TMDX, and PODD HeadlinesRecent News About These CompaniesTransMedics Group, Inc. (TMDX): A Bull Case TheoryJune 9 at 10:25 AM | insidermonkey.comTransMedics Group, Inc. (TMDX): A Bull Case TheoryJune 9 at 9:47 AM | finance.yahoo.com3 Medical Technology Stocks Outperforming in 2025 (TMDX)June 9 at 7:29 AM | marketbeat.comGAMMA Investing LLC Boosts Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)June 9 at 4:01 AM | marketbeat.comTransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationJune 8 at 10:00 AM | accessnewswire.com12,523 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Two Sigma Investments LPJune 8 at 3:32 AM | marketbeat.comStocks With Rising Composite Ratings: TransMedics GroupJune 6 at 1:59 PM | msn.comTransMedics Group (NASDAQ:TMDX) Earns "Overweight" Rating from Piper SandlerJune 6 at 1:33 AM | americanbankingnews.com3 High-Growth Stocks Traders Love and Investors Should Watch (TMDX)June 5, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to ConnectJune 5, 2025 | accessnewswire.comSugar Maple Asset Management LLC Makes New $740,000 Investment in TransMedics Group, Inc. (NASDAQ:TMDX)June 5, 2025 | marketbeat.comTransMedics Group's (TMDX) Hold Rating Reiterated at Needham & Company LLCJune 5, 2025 | americanbankingnews.comPiper Sandler Boosts TransMedics (TMDX) PT to $145, Keeps Overweight RatingJune 4, 2025 | msn.comTransMedics Group's (TMDX) "Overweight" Rating Reiterated at Piper SandlerJune 4, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities InvestigationJune 3, 2025 | accessnewswire.comTransMedics Group's (TMDX) "Hold" Rating Reaffirmed at Needham & Company LLCJune 3, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX) and Merck & Company (MRK)June 3, 2025 | theglobeandmail.comWellington Management Group LLP Cuts Position in TransMedics Group, Inc. (NASDAQ:TMDX)June 3, 2025 | marketbeat.comTransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?June 2, 2025 | zacks.comUniversal Beteiligungs und Servicegesellschaft mbH Buys New Shares in TransMedics Group, Inc. (NASDAQ:TMDX)June 2, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Investors to Inquire about Securities InvestigationJune 1, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsInsulet Surges on Q1 Beat, Emerges as a Top S&P 500 PerformerBy Jeffrey Neal Johnson | May 14, 2025View Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer3 Medical Technology Stocks Outperforming in 2025By Ryan Hasson | June 9, 2025View 3 Medical Technology Stocks Outperforming in 20253 High-Growth Stocks Traders Love and Investors Should WatchBy Chris Markoch | June 5, 2025View 3 High-Growth Stocks Traders Love and Investors Should WatchGRAL, TMDX, and PODD Company DescriptionsGrail NASDAQ:GRAL$40.03 +1.67 (+4.35%) Closing price 04:00 PM EasternExtended Trading$39.99 -0.04 (-0.10%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.Insulet NASDAQ:PODD$305.66 -6.11 (-1.96%) Closing price 04:00 PM EasternExtended Trading$303.42 -2.25 (-0.73%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.TransMedics Group NASDAQ:TMDX$139.40 +0.35 (+0.25%) Closing price 04:00 PM EasternExtended Trading$139.44 +0.04 (+0.03%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Science Applications International Is a Wicked Hot Buy in June Why Unity Software May Be the AI Breakout No One Saw Coming Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead? Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
